Literature DB >> 25095884

Temporal trends in patient characteristics and outcomes among Medicare beneficiaries undergoing primary prevention implantable cardioverter-defibrillator placement in the United States, 2006-2010. Results from the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.

Ryan T Borne1, Pamela N Peterson2, Robert Greenlee2, Paul A Heidenreich2, Yongfei Wang2, Jeptha P Curtis2, Wendy S Tzou2, Paul D Varosy2, Mark S Kremers2, Frederick A Masoudi2.   

Abstract

BACKGROUND: Contemporary patterns of use and outcomes of implantable cardioverter-defibrillators (ICDs) in community practice settings are not well characterized. We assessed temporal trends in patient characteristics and outcomes among older patients undergoing primary prevention ICD therapy in US hospitals between 2006 and 2010. METHODS AND
RESULTS: Using the National Cardiovascular Data Registry's ICD Registry, we identified Medicare fee-for-service beneficiaries aged ≥65 years and older with left ventricular ejection fraction ≤35% who underwent primary prevention ICD implantation, including those receiving concomitant cardiac resynchronization therapy between 2006 and 2010 and could be matched to Medicare claims. Outcomes were mortality and hospitalization (all-cause and heart failure) at 180 days, and device-related complications. We used multivariable hierarchical logistic regression to assess temporal trends in outcomes accounting for changes in patient, physician, and hospital characteristics. The cohort included 117 100 patients. Between 2006 and 2010, only modest changes in patient characteristics were noted. Fewer single lead devices and more cardiac resynchronization therapy devices were used over time. Between 2006 and 2010, there were significant improvements in all outcomes, including 6-month all cause mortality (7.1% in 2006, 6.5% 2010; adjusted odds ratio, 0.88; 95% confidence interval, 0.82-0.95), 6-month rehospitalization (36.3% in 2006, 33.7% in 2010; adjusted odds ratio, 0.87; 95% confidence interval, 0.83-0.91), and device-related complications (5.8% in 2006, 4.8% in 2010; adjusted odds ratio, 0.80; 95% confidence interval, 0.74-0.88).
CONCLUSIONS: The clinical characteristics of this national population of Medicare patients undergoing primary prevention ICD implantation were stable between 2006 and 2010. Simultaneous improvements in outcomes suggest meaningful advances in the care for this patient population.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  implantable cardioverter-defibrillators; outcomes research; quality; registries

Mesh:

Year:  2014        PMID: 25095884     DOI: 10.1161/CIRCULATIONAHA.114.008653

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

1.  Predicting cardiac events using ventricular dyssynchrony in patients who received implantable cardioverter defibrillators: Are more treatment options required?

Authors:  Keiichiro Yoshinaga
Journal:  J Nucl Cardiol       Date:  2015-11-24       Impact factor: 5.952

2.  Implantable cardioverter defibrillators: even better than we thought?

Authors:  Una Buckley; Kalyanam Shivkumar
Journal:  Eur Heart J       Date:  2015-05-05       Impact factor: 29.983

Review 3.  Implantable Cardioverter-Defibrillator Use in Older Adults: Proceedings of a Hartford Change AGEnts Symposium.

Authors:  Daniel B Kramer; Daniel D Matlock; Alfred E Buxton; Nathan E Goldstein; Carol Goodwin; Ariel R Green; James N Kirkpatrick; Christopher Knoepke; Rachel Lampert; Paul S Mueller; Matthew R Reynolds; John A Spertus; Lynne W Stevenson; Susan L Mitchell
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-06-02

4.  Influence of Multimorbidity on Burden and Appropriateness of Implantable Cardioverter-Defibrillator Therapies.

Authors:  Alexandra M Hajduk; Jerry H Gurwitz; Grace Tabada; Frederick A Masoudi; David J Magid; Robert T Greenlee; Sue Hee Sung; Andrea E Cassidy-Bushrow; Taylor I Liu; Kristi Reynolds; David H Smith; Frances Fiocchi; Robert Goldberg; Thomas M Gill; Nigel Gupta; Pamela N Peterson; Claudio Schuger; Humberto Vidaillet; Stephen C Hammill; Heather Allore; Alan S Go
Journal:  J Am Geriatr Soc       Date:  2019-03-20       Impact factor: 5.562

5.  Exercise Interventions in Patients With Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Authors:  Daniel A Steinhaus; Steven A Lubitz; Peter A Noseworthy; Daniel B Kramer
Journal:  J Cardiopulm Rehabil Prev       Date:  2019-09       Impact factor: 2.081

6.  Utilization and in-hospital complications of cardiac resynchronization therapy: trends in the United States from 2003 to 2013.

Authors:  Seyed Mohammadreza Hosseini; Kasra Moazzami; Guy Rozen; Jeena Vaid; Ahmed Saleh; Kevin E Heist; Mark Vangel; Jeremy N Ruskin
Journal:  Eur Heart J       Date:  2017-07-14       Impact factor: 29.983

Review 7.  [ICD in elderly patients].

Authors:  Carsten W Israel
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-03

8.  Use of Cardiac Resynchronization Therapy Among Eligible Patients Receiving an Implantable Cardioverter Defibrillator: Insights From the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry.

Authors:  Lucas N Marzec; Pamela N Peterson; Haikun Bao; Jeptha P Curtis; Frederick A Masoudi; Paul D Varosy; Steven M Bradley
Journal:  JAMA Cardiol       Date:  2017-05-01       Impact factor: 14.676

9.  Natural History of Implantable Cardioverter-Defibrillator Implanted at or after the Age of 70 years in a Veteran Population: A Single Center Study.

Authors:  Tarek Ajam; Vikas Kalra; Changyu Shen; Xiaochen Li; Sandeep Gautam; Thomas Kambur; Mamta Barmeda; Kyle W Yancey; Samer Ajam; Jason Garlie; John M Miller; Rahul Jain
Journal:  J Atr Fibrillation       Date:  2016-12-31

10.  Hospice Use Following Implantable Cardioverter-Defibrillator Implantation in Older Patients: Results From the National Cardiovascular Data Registry.

Authors:  Daniel B Kramer; Matthew R Reynolds; Sharon-Lise Normand; Craig S Parzynski; John A Spertus; Vincent Mor; Susan L Mitchell
Journal:  Circulation       Date:  2016-03-25       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.